InsiderTrades

Form 4 for CAMP Camp4 Therapeutics Corp

Accepted 2024-10-17 00:00:00 ET · period of report 2024-10-15 · accession 0001415889-24-025354 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2024-10-17 2024-10-15 CAMP Everest Aggregator, LP 10% C - Cnv Deriv — +2.42M 2.42M New —
DI 2024-10-17 2024-10-15 CAMP Everest Aggregator, LP 10% P - Purchase $11.00 +1.36M 3.79M +56% +$15.00M
DI 2024-10-17 2024-10-15 CAMP Everest Aggregator, LP 10% C - Cnv Deriv — -27.17M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-15 C A 2,422,166 — 2,422,166 I By Everest Aggregator, LP — — (F1) Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. (F2) Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
2 Common Common Stock 2024-10-15 P A 1,363,636 $11.00 3,785,802 I By Everest Aggregator, LP — — (F2) Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
3 Derivative Series B Preferred Stock 2024-10-15 C D 27,166,530 — 0 I By Everest Aggregator, LP — · — to — 2,422,166 Common Stock (F1) Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. (F2) Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.